Lockheed Martin Corp. (0R3E)
London Exchange · UK · prices in USD · close of 22 Oct 2026
Key indicators
| Last close | USD 585.63 |
|---|---|
| 52-week range | 437.34 – 719.00 |
| Return, 1 month / 3 months | +12.7% / +14.3% |
| Return, 1 year / 3 years | +23.9% / +42.4% |
| Trend | Uptrend |
| RSI (14) | 74 |
| Volatility (1 year) | 27.9% |
| Worst drawdown (1 year) | -26.0% |
| Average daily value traded | 1.52M USD |
| Dividend yield | 2.4% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Lockheed Martin is an American aerospace and defence company based in Bethesda, Maryland. It designs and builds military aircraft, including fighter jets, transport planes and helicopters, and produces missiles, missile defence systems and space hardware. Its customers are mainly government defence and security agencies, particularly in the United States, along with allied nations. The company also provides support services, maintenance and training for the equipment it supplies, and works on space and satellite programmes for government and institutional customers.
On this site Lockheed Martin Corp. appears as a stock on the London Exchange (UK), code 0R3E, with prices in US dollars (USD). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Lockheed Martin Corp. (0R3E) trades on the London Exchange in UK. It last closed at USD 585.63 on 22 October 2026.
Its price-based Market X-Ray is 61 out of 100 (a fair price profile), ranking 1,245 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 23.9% and over the last three months it rose 14.3%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 53 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 4.7% | ||
| From 52-week high | -12.7% | ||
| Momentum | 69 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 14.3% | ||
| 6-month return | 6.9% | ||
| 12-month return, skipping the last month | 9.9% | ||
| Stability (higher is calmer) | 63 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 27.9% | ||
| Worst drawdown, 1 year (smaller is calmer) | -26.0% | ||
| Liquidity | 57 · Fair | Moderate trading activity. | |
| Average daily value traded | 1.52M USD | ||
| Zero-volume days | 0.0% | ||
| Income | 62 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 2.4% | ||
| Years with dividends | 6 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | +10.2% |
|---|---|
| 1 month | +12.7% |
| 3 months | +14.3% |
| 6 months | +6.9% |
| 1 year | +23.9% |
| 3 years | +42.4% |
| 5 years | +77.8% |
Signals
| 50-day / 200-day average | 540.29 / 559.50 |
|---|---|
| Golden / death cross (60 days) | Death, 18 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 18.64 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 28 Aug 2026 | USD 3.4500 |
| 29 May 2026 | USD 3.4500 |
| 27 Feb 2026 | USD 3.4500 |
| 28 Nov 2025 | USD 3.4500 |
| 1 Sep 2025 | USD 3.3000 |
| 30 May 2025 | USD 3.3000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.